Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Orilissa (AbbVie)
- INDICATIONS: indicated for the management of moderate to severe pain associated with endometriosis.
- CLASS: Gonadotropin-releasing hormone (GnRH) antagonist
- HALF-LIFE: 4–6 hours
- FDA APPROVAL DATE: 07/23/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Exposure early in pregnancy may increase the risk of early pregnancy loss.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of elagolix in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/04/2024
